Press Releases

03/27/2019

IQN Path Selects SeraCare Life Sciences for First-Ever Tumor Mutational Burden External Quality Assessment Program

SeraCare Life Sciences, a manufacturer and leading partner to global in vitro diagnostics manufacturers and clinical laboratories, announced today their successful selection as a technology partner in support of the first ever tumor mutational burden (TMB) external quality assessment (EQA) program being developed by the International Quality Network for Pathology (IQN Path).

10/29/2018

SeraCare Announces Exclusive Partnership with AccuRef Diagnostics

SeraCare Life Sciences, a manufacturer and leading partner to global in vitro diagnostics manufacturers and clinical laboratories, announced today an exclusive partnership with AccuRef Diagnostics, a Division of Applied StemCell, Inc., to market and sell their broad portfolio of CRISPR-engineered cell line reference materials.

10/22/2018

SeraCare Announces Launch of Expanded NTRK Reference Material Panel

SeraCare Life Sciences, a manufacturer and leading partner to global in vitro diagnostics manufacturers and clinical laboratories, announced today the commercial launch of an expanded neurotrophic tropomyosin receptor kinase (NTRK) RNA fusion reference material panel developed in a partnership with Bayer.

News

09/24/2019

FNIH Biomarkers Consortium Launches Project that will Standardize the Measurement of Genetic Blood Tests to Track Cancer

The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium has launched a new project under its Cancer Steering Committee that will standardize the assessment of genetic tests that use blood samples to track cancer in hospitals and laboratories across the United States. In particular, the project will develop tools to enable clinicians to measure and confidently compare circulating tumor DNA (ctDNA) test results across different laboratories.

04/22/2019

SeraCare to Develop NGS Standards for Tumor Mutational Burden Monitoring

SeraCare Life Sciences, Milford, Mass, a provider of quality control materials for the infectious disease testing and next-generation sequencing (NGS) markets, has been selected as a technology partner in support of the first-ever external quality assessment program for tumor mutational burden monitoring, which is being developed by the International Quality Network for Pathology (IQN Path).

04/12/2019

Making the Shift from Technological Innovation to Operational Excellence: Delivering on the Promise of Next-Generation Sequencing for Personalized Medicine

Targeted therapies and now recently, immunotherapies, have demonstrated great promise towards increasing response rates, as well as duration of response for cancer patients. This is often achieved by understanding biomarkers associated with therapeutic response and then stratifying patients accordingly. In many cases, this is accomplished through the application of companion diagnostics which have been developed using various approaches including immunohistochemistry, polymerase chain reaction (PCR), and more recently, next‑generation sequencing (NGS).